Overview Financials News + Filings Key Docs Charts Ownership Insiders |
HTG MOLECULAR DIAGNOSTICS, INC (HTGM)
|
Add to portfolio |
|
|
Price: |
$4.78
| | Metrics |
OS: |
2.21
|
M
| |
|
|
Market cap: |
$10.6
|
M
| |
|
|
Net cash:
|
$6.56
|
M
| |
$2.96
|
per share
|
EV:
|
$4.02
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
|
| |
|
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
Revenues | 8.9 | 8.5 | 19.2 | 21.5 | 14.8 | 5.1 | 4.0 | 3.3 |
Revenue growth | 4.2% | -55.5% | -10.7% | 45.7% | 187.6% | 27.0% | 21.4% | -99.9% |
Cost of goods sold | 4.1 | 4.0 | 8.9 | 5.1 | 5.0 | 4.1 | 3.3 | 3.2 |
Gross profit | 4.8 | 4.6 | 10.3 | 16.4 | 9.8 | 1.0 | 0.7 | 0.1 |
Gross margin | 54.0% | 53.3% | 53.6% | 76.3% | 66.3% | 19.4% | 17.5% | 3.7% |
Selling, general and administrative | 16.5 | 18.1 | 18.7 | 20.0 | 17.5 | 17.4 | 15.0 | 9.9 |
Research and development | 6.1 | 6.1 | 10.6 | 12.6 | 10.0 | 7.9 | 4.6 | 3.1 |
EBIT | -17.8 | -19.6 | -19.0 | -16.2 | -17.7 | -24.3 | -18.9 | -12.8 |
EBIT margin | -200.1% | -229.1% | -98.7% | -75.1% | -120.1% | -474.0% | -467.4% | -386.0% |
Pre-tax income | -17.1 | -20.9 | -19.3 | -16.5 | -19.0 | -26.0 | -21.4 | -14.0 |
Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | | | | | | | | 0.0% |
Net income | -17.1 | -20.9 | -19.3 | -16.5 | -19.0 | -26.0 | -22.7 | -17.6 |
Net margin | -192.5% | -244.1% | -100.5% | -76.5% | -128.5% | -507.3% | -562.3% | -529.3% |
|
Diluted EPS | ($2.47) | ($4.51) | ($7.60) | ($0.60) | ($1.79) | ($3.66) | ($5.03) | ($175.03) |
Shares outstanding (diluted) | 6.9 | 4.6 | 2.5 | 27.5 | 10.6 | 7.1 | 4.5 | 0.1 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|